About this trial
The goal of this clinical trial is to learn whether spinal cord stimulation (SCS) is effective in treating post-stroke spasticity in adults. It will also evaluate the safety of the implanted SCS system. The main questions it aims to answer are:
1. Does active SCS reduce limb spasticity compared with sham stimulation? 2. What device-related problems do participants experience during the study?
All participants receive the same implantation and programming procedures,but no therapeutic stimulation(0 mA) for sham SCS group duringthe first 6 weeks after randomization.
Participants will:
1. Have an SCS system surgically implanted 2. Be randomly assigned to receive active SCS or sham SCS for 6 weeks 3. After completion of the 6-week randomized comparison period, active stimulation will be initiated for all participants. 4. Attend a post-operative visit within 3 to 7 days after surgery for device activation or sham activation, programming, safety checks, and study assessments 5. Attend follow-up visits for study assessments at approximately 6, 12, 24 weeks, 1 year and 2 years after randomization 6. Complete assessments of muscle spasticity, joint range of motion, motor function, walking ability, daily functioning, pain, and quality of life 7. Report any medical problems or device-related problems during the study
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged ≥18 years and <75 years, regardless of sex;
Diagnosed with ischemic or hemorrhagic stroke, with unilateral or single-limb motor dysfunction persisting for at least 6 months;
The primary brain lesion and its underlying cause are clinically stable;
Presence of unilateral upper- or lower-limb spasticity, with a Modified Ashworth Scale (MAS) grade of ≥2 in at least two muscle groups of the affected limb;
Disqualifiers
Any contraindication to spinal cord stimulation surgery;
Uncontrolled refractory epilepsy;
Presence of tonic spasticity, such as decorticate rigidity or decerebrate rigidity;
Poorly controlled severe psychiatric or cognitive impairment, defined as a Beck Depression Inventory-II score >25 or a Mini-Mental State Examination score <24;
Trial design
Parallel
Treatments tested in this trial
Active spinal cord stimulation
DeviceParticipants will receive therapeutic electrical stimulation through the implanted spinal cord stimulation system beginning on Day 0, defined as the day of active or sham activation within 3-7 days after surgery. An individualized SCS programming strategy will be used. Initial stimulation parameters will include a frequency of 40-60 Hz, a pulse width of 200-300 μs, and a low starting amplitude that will be gradually increased according to participant tolerance. For participants with concomitant conditions such as pain, the stimulation frequency may be increased as clinically appropriate. Intermittent stimulation will be preferred, and electrode contact combinations will be individually selected. Active stimulation will continue through the 24-week follow-up
Sham spinal cord stimulation
DeviceParticipants will undergo the same implantation and programming procedures. On Day 0, the implanted system will be turned on, but the stimulation amplitude will be set to 0 mA so that no effective electrical stimulation is delivered during the 6-week randomized comparison period. After completion of the Week 6 assessment, participants will receive active SCS using the same individualized programming principles as the Active SCS Group. Active stimulation will continue through the 24-week follow-up.
Treatment groups
Trial outcomes
Primary outcomes
Change in Mean Modified Ashworth Scale Score of the Primary Target Muscle Groups From Baseline to Week 6
The primary outcome is the change in the mean Modified Ashworth Scale (MAS) score of the Primary Target Muscle Groups from baseline to Week 6. The Primary Target Muscle Groups are selected from a upper or lower limb before treatment and must include at least two muscle groups. For the upper limb, eligible muscle groups include the shoulder adductors, shoulder internal rotators, elbow flexors, elbow extensors, forearm pronators, wrist flexors, and finger flexors. For the lower limb, eligible muscle groups include the hip flexors, hip adductors, hip internal rotators, knee flexors, knee extensors, and ankle plantar flexors. For analysis, the original MAS grades are converted to a 0-5 numerical scale, with grade 1+ converted to 2 and grades 2, 3, and 4 converted to 3, 4, and 5, respectively. The mean MAS score is calculated across the selected Primary Target Muscle Groups. Change is calculated as the Week 6 mean MAS score minus the baseline mean MAS score.
Secondary outcomes
Change in Modified Ashworth Scale Scores of the Primary Target Muscle Groups From Baseline
Change in MAS of the primary target muscle groups from baseline to day 0, week 6, week 12, week 24, 1 year and 2 years after randomization
Proportion of Participants With an Improvement in Mean Modified Ashworth Scale Score of at Least 1 Point
A participant is defined as a responder when the mean MAS score of the Primary Target Muscle Groups decreases by at least 1 point compared with baseline. The outcome is reported as the proportion of responders at each assessment.
Change in Active and Passive Joint Range of Motion From Baseline
Active and passive range of motion are measured in degrees for movements corresponding to the assessed muscle groups. Upper-limb measurements include shoulder abduction, shoulder external rotation, elbow extension, elbow flexion, forearm supination, wrist extension, and metacarpophalangeal joint extension. Lower-limb measurements include hip extension, hip abduction, hip external rotation, knee extension, knee flexion, and ankle dorsiflexion. A greater range generally indicates better joint mobility.
Change in Fugl-Meyer Assessment Score From Baseline
The Fugl-Meyer Assessment (FMA) is used to assess motor and sensory function. The upper-limb motor score ranges from 0 to 66, and the lower-limb motor score ranges from 0 to 34. Light touch sensation is assessed at the upper arm, palm, thigh, and sole, with each site scored from 0 to 2, giving a total score of 0 to 8. Proprioception is assessed at the shoulder, elbow, wrist, thumb, hip, knee, ankle, and toe joints, with each site scored from 0 to 2, giving a total score of 0 to 16. Higher scores indicate better motor and sensory function.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Beijing Pins Medical Co., Ltd
Lead sponsor
China-Japan Friendship Hospital
Collaborator
Beijing Sanbo Brain Hospital
Collaborator
Xuanwu Hospital, Beijing
Collaborator
Beijing Tiantan Hospital
Collaborator
Beijing Chao Yang Hospital
Collaborator
Beijing Tsinghua Changgeng Hospital
Collaborator
Xiangya Hospital of Central South University
Collaborator
West China Hospital
Collaborator
First Affiliated Hospital, Sun Yat-Sen University
Collaborator
RenJi Hospital
Collaborator
Qilu Hospital of Shandong University
Collaborator
The First Affiliated Hospital of Zhengzhou University
Collaborator
Nanjing Brain Hospital
Collaborator
Second Affiliated Hospital, Zhejiang University, School of Medicine
Collaborator
First Affiliated Hospital of Xinjiang Medical University
Collaborator
Peking University Aerospace Center Hospital
Collaborator
Anhui Provincial Hospital
Collaborator